Halozyme jumps after FDA lifts hold on subcutaneous Cinryze

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.54 (24%) to $7.95 on Friday after it and partner ViroPharma Inc. (NASDAQ:VPHM)

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE